Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulodexide in overt type 2 diabetic nephropathy
2005-002095-15Phase 3Terminated
- Sponsor
- Keryx Biopharmaceuticals
- Start
- Aug 2005
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) comparing Sulodexide with Placebo (2 arms). Primary endpoint: Time to first composite renal endpoint. Started Aug 2005; status: terminated.
02
Drugs
sulodexide
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-002095-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002095-15.